N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
List view / Grid view
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
The discovery of early plasma biomarkers for Alzheimer's disease could transform outcomes by enabling patients to begin treatment early.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
A research team has discovered how proteins called pioneer transcription factors turn on vital genes in cells.
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
Researchers have revealed how the most severe cases of G6PD deficiency occur, which could help scientists design new drugs for the disease.
Researchers have developed a new technique that that could one day enable us to grow fully functional human organs in the laboratory.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
Treating only a few nerve cells with the hyper-interleukin-6 (hIL-6) gene therapy stimulated the regeneration of nerves.